Naval Daver

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.

P. Sharma, F. Ravandi, N. Daver, 2017, Advances in experimental medicine and biology.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

Susan O'Brien, Koji Sasaki, Naveen Pemmaraju, 2018, The Lancet. Haematology.

The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia

H. Kantarjian, S. Verstovsek, F. Ravandi, 2012, Clinical Cancer Research.

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

Guillermo Garcia-Manero, Angela Teng, H. Kantarjian, 2015, Leukemia & lymphoma.

A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)

Hui Yang, Simona Colla, Xuelin Huang, 2016 .

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

Jorge Cortes, Guillermo Garcia-Manero, Gautam Borthakur, 2013, Blood.

Adhesion Signaling States in AML

Kevin R. Coombes, Chenyue W. Hu, Amina A. Qutub, 2014 .

The emerging role of immune checkpoint based approaches in AML and MDS

James Allison, Guillermo Garcia-Manero, P. Sharma, 2018, Leukemia & lymphoma.